Wan Jia, Zhang Xianghong, Liu Tang, Zhang Xiangsheng
Department of Orthopedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, P.R. China.
Oncol Lett. 2016 Jan;11(1):511-520. doi: 10.3892/ol.2015.3962. Epub 2015 Nov 24.
Osteosarcoma (OS) is a frequently observed primary malignant tumor. Current therapy for osteosarcoma consists of comprehensive treatment. The long-term survival rate of patients exhibiting nonmetastatic OS varies between 65-70%. However, a number of OS cases have been observed to be resistant to currently used therapies, leading to disease recurrence and lung metastases, which are the primary reasons leading to patient mortality. In the present review, a number of pieces of evidence provide support for the potential uses of immunotherapy, including immunomodulation and vaccine therapy, for the eradication of tumors via upregulation of the immune response. Adoptive T-cell therapy and oncolytic virotherapy have been used to treat OS and resulted in objective responses. Immunologic checkpoint blockade and targeted therapy are also potentially promising therapeutic tools. Immunotherapy demonstrates significant promise with regard to improving the outcomes for patients exhibiting OS.
骨肉瘤（OS）是一种常见的原发性恶性肿瘤。目前骨肉瘤的治疗包括综合治疗。非转移性骨肉瘤患者的长期生存率在65%至70%之间。然而，已观察到一些骨肉瘤病例对目前使用的治疗方法耐药，导致疾病复发和肺转移，这是导致患者死亡的主要原因。在本综述中，大量证据支持免疫疗法（包括免疫调节和疫苗疗法）通过上调免疫反应来根除肿瘤的潜在用途。过继性T细胞疗法和溶瘤病毒疗法已用于治疗骨肉瘤并产生了客观反应。免疫检查点阻断和靶向治疗也是潜在有前景的治疗工具。免疫疗法在改善骨肉瘤患者的治疗结果方面显示出巨大潜力。
